The FTC’s Health Care Work
When health care markets are competitive, consumers benefit from lower costs, better care and more innovation. The Federal Trade Commission enforces the antitrust laws in health care markets to prevent anticompetitive conduct that would deprive consumers of the benefits of competition. The agency also gives guidance to participants in the health care market - including physicians and other health professionals, hospitals and other institutional providers, pharmaceutical companies and other sellers of health care products, and insurers - to help them comply with U.S. antitrust laws. The FTC maintains its expertise in health care markets by doing research and issuing reports on competition issues, which in the past have included empirical studies of generic drug entry, contact lens sales, and mail order pharmacies, and economic analyses of the effects of mergers involving non-profit hospitals.
- GoodRx Holdings, Inc. ( )
- LCA-Vision Inc. d/b/a LasikPlus ( )
- Illumina, Inc., and GRAIL, Inc., In the Matter of ( )
- San Juan IPA, Inc. ( )
- ALG-Health LLC, et al., U.S. v. ( )
- Benefytt Technologies, et al., FTC v. ( )
- RWJ Barnabas Health/Saint Peter's Healthcare System, In the Matter of ( )
- Hackensack Meridian Health, Inc. and Englewood Healthcare Foundation, In the Matter of ( )
- Medtronic/Intersect, In the Matter of ( )
- AH Media Group, LLC ( )
- HCA Healthcare/Steward Health Care System, In the Matter of ( )
- Lifespan/CNE, In the Matter of ( )
- Boston Scientific and BTG, In the Matter of ( )
- Vision Path, Inc., d/b/a Hubble Contacts, U.S. v. ( )
- Vyera Pharmaceuticals, LLC ( )
- ANI/Novitium, In the Matter of ( )
- Board of Dental Examiners of Alabama, In the Matter of ( )
- Bristol-Myers Squibb Company and Celgene Corporation, In the Matter of ( )
- Nordic Clinical, Inc. and Encore Plus Solutions, Inc. ( )
- AbbVie Inc., et al. ( )
- FTC Order to Bar ZyCal Bioceuticals from Deceptive Health Marketing ( )
- FTC Asks Federal Court to Hold ‘Pharma Bro’ Martin Shkreli in Contempt ( )
- FTC Order Requires LasikPlus to Pay for its Bait-and-Switch Eye Surgery Ads ( )
- FTC Announces New Business Guidance for Marketers and Sellers of Health Products ( )
- FTC Proposes Updating Eyeglass Rule to Require Prescribers to Get Signed Confirmation When Providing a Prescription to Their Patients ( )
- FTC Amicus Brief Challenges Abuse of FDA “Orange Book” Listing Procedures to Block Drug Competition ( )
- FTC Approves Final Order against JAB Consumer Partners to Protect Pet Owners from Private Equity Firm’s Rollup of Veterinary Services Clinics ( )
- FTC Staff Opposes Proposed Certificate of Public Advantage That Could Shield SUNY Upstate Medical University’s Acquisition of Crouse Health System from Antitrust Scrutiny ( )
- New Mexico Physician Association to Pay $263,000 Civil Penalty to Settle FTC Allegations That it Violated 2005 Order ( )
- Administrative Law Judge Dismisses FTC’s Challenge of Illumina’s Proposed Acquisition of Cancer Detection Test Maker Grail ( )
- FTC Returning More Than $1.9 Million to Consumers Nationwide Who Purchased Hubble Contact Lenses Without Properly Obtained or Verified Prescriptions ( )
- FTC Policy Paper Warns About Pitfalls of COPA Agreements for Patient Care and Healthcare Workers ( )
- FTC Action Against Benefytt Results in $100 Million in Refunds for Consumers Tricked into Sham Health Plans and Charged Exorbitant Junk Fees ( )
- FTC Approves Final Order Protecting Pet Owners from Private Equity Firm’s Anticompetitive Acquisition of Veterinary Services Clinics ( )
- FTC Approves Final Order Preserving Competition for Development and Marketing of Steroid Injectable Drug ( )
- FTC Approves Final Order Protecting Patients Who Rely on Medical Instruments Used in Sinus Procedures ( )
- FTC Takes Second Action Against JAB Consumer Partners to Protect Pet Owners from Private Equity Firm’s Rollup of Veterinary Services Clinics ( )
- Federal Trade Commission Returns More Than $5.4 Million to Consumers ( )
- FTC to Ramp Up Enforcement Against Any Illegal Rebate Schemes, Bribes to Prescription Drug Middleman That Block Cheaper Drugs ( )
- Statement of Bureau of Competition Director Holly Vedova Regarding the Decision of Utah Healthcare Competitors HCA Healthcare and Steward Health Care System to Abandon Their Proposed Merger ( )
- I’ll pay you to give this blog post five stars(January 25, 2022)
- Abracadabra: Bad reviews be gone (January 25, 2022)
- Physician Group and Healthcare Facility Merger Study(April 14, 2021)
- A prescription for complying with the Eyeglass Rule(December 8, 2020)
- MMA Reports: No tricks or treats—just facts(October 27, 2020)
- FTC updates the Contact Lens Rule: What it means for prescribers and sellers(June 23, 2020)
- Then, now, and down the road: Trends in pharmaceutical patent settlements after FTC v. Actavis(May 28, 2019)
- Control no longer controlling for HSR reporting of not-for-profit combinations(October 26, 2018)
- Insights into contact lenses: FTC workshop will focus on the Contact Lens Rule(March 1, 2018)
- Quo Vadis Post-Actavis?(March 30, 2016)
- Antitrust Violation vs. Injury-in-Fact: A distinction that makes a difference(February 26, 2016)
- Is FTC v. Actavis Causing Pharma Companies to Change Their Behavior?(January 13, 2016)
- Monitors: Expert eyes and ears in Commission orders(July 14, 2015)
- From the antitrust mailbag: What can the FTC do about prescription drug price spikes?(May 18, 2015)
- Power shopping for an alternative buyer(March 31, 2015)
- PrivacyCon 2021July 27, 2021
- PrivacyCon 2020July 21, 2020
- FDA / FTC Workshop on a Competitive Marketplace for BiosimilarsMarch 9, 2020
- A Health Check on COPAs: Assessing the Impact of Certificates of Public Advantage in Healthcare MarketsJune 18, 2019
- Understanding Competition in Prescription Drug Markets: Entry and Supply Chain DynamicsNovember 8, 2017
- Now Hear This: Competition, Innovation, and Consumer Protection Issues in Hearing Health CareApril 18, 2017
- Examining Health Care CompetitionFebruary 24, 2015
- Conditional Pricing Practices: Economic Analysis and Legal Policy ImplicationsJune 23, 2014
- Examining Health Care CompetitionMarch 20, 2014
- Follow-On Biologics Workshop: Impact of Recent Legislative and Regulatory Naming Proposals on CompetitionFebruary 4, 2014
- Consumer Protection and the Healthcare MarketplaceSeptember 19, 2013
- Senior Identity Theft: A Problem in This Day and AgeMay 7, 2013
- Pet Medications Workshop October 2, 2012
- Another Dose of Competition: Accountable Care Organizations and AntitrustMay 9, 2011
- Workshop Regarding Accountable Care Organizations and Implications Regarding Antitrust, Physican Self-Referral, Anti-Kickback and Civil Monetary Penalty (CMP) LawsOctober 5, 2010
- Emerging Health Care Competition and Consumer Issues: Competition Issues Involving Follow-on Biologic DrugsNovember 21, 2008
- Emerging Health Care Competition and Consumer Issues: Competitive Significance of Health Care Quality InformationOctober 30, 2008
- Clinical Integration in Health Care: A Check-UpMay 29, 2008
- Innovations in Health Care DeliveryApril 24, 2008
- Health Care Information and Competition conferenceApril 16, 2004
- Remarks of Chair Lina M. Khan at the American Economic Liberties Project and the National Community Pharmacists Association Event Titled How Pharmacy Benefit Managers Impact Drug Prices, Communities, and Patients ( )
- Statement of Commissioner Christine S. Wilson Regarding the FTC Policy Statement on Rebates and Fees in Exchange for Excluding Lower Cost Drug Products ( )
- Remarks of Chair Lina M. Khan Regarding Policy Statement on Rebates and Fees in Exchange for Excluding Lower-Cost Drug Products ( )
- Statement of Commissioner Alvaro M. Bedoya Regarding the Commission's Policy Statement on Rebates and Fees in Exchange for Excluding Lower-Cost Drug Products ( )
- Policy Statement of the Federal Trade Commission on Rebates and Fees in Exchange for Excluding Lower Cost Drug Products ( )
- Oral Remarks of Christine S. Wilson at Open Commission Meeting on June 16, 2022 ( )
- Statement of Commissioner Rebecca Kelly Slaughter Regarding the Policy Statement of the Federal Trade Commission on Rebates and Fees in Exchange for Excluding Lower-Cost Drug Products ( )
- Keynote Remarks of Commissioner Rebecca Kelly Slaughter at the FTC/DOJ Pharmaceutical Task Force Workshop ( )
- Statement of Commissioner Rebecca Kelly Slaughter Regarding 6(b) Study of Pharmacy Benefit Managers ( )
- Statement of Chair Lina M. Khan Regarding 6(b) Study of Pharmacy Benefit Managers ( )
- Concurring Statement of Commissioners Noah Joshua Phillips and Christine S. Wilson Regarding 6(b) Study of Pharmacy Benefit Managers ( )
- Concurring Statement of Commissioner Slaughter and Chair Khan regarding FTC and State of Rhode Island v. Lifespan Corporation and Care New England Health System ( )
- Remarks of Chair Lina M. Khan Regarding the 6(b) Study on Pharmacy Benefit Managers ( )
- Concurring Statement of Commissioners Noah Joshua Phillips and Christine S. Wilson Regarding Lifespan Corporation and Care New England Health System ( )
- Stopping COVID-19 Fraud and Price Gouging ( )
- Statement of Chair Lina M. Khan on the Ruling by Judge Denise L. Cote Regarding Federal Trade Commission et al v. Vyera Pharmaceuticals, LLC et al Regarding ( )
- Dissenting Remarks of Commissioner Noah Joshua Phillips Regarding the Commission's Issuance of Seven Omnibus Resolution ( )
- Dissenting Statement of Commissioner Christine S. Wilson ( )
- Statement of Commissioner Rohit Chopra regarding the Review of the FTC's Pharmaceutical Merger Enforcement Program ( )
- Statement of Commissioners Noah Joshua Phillips and Christine S. Wilson regarding the Multilateral Pharmaceutical Merger Task Force ( )
- Staff Opinion Letter Concerning Discounted Pharmaceuticals and Medical Devices Under the Non-Profit Institutions Act ( )
- Letter From Markus H. Meier, Assistant Director, Bureau of Competition, Concerning Crouse Health Hospital's Proposal To Sell Discounted Pharmaceutical Products to the Employees, Retirees, and Their Dependents of Its Affiliate, Dated October 20, 2017 ( )
- American Medical Association ( )
- Advisory opinion on the permissibility under the antitrust laws of a system of professional society peer review of physicians' fees ( )
- Advisory opinion on the application of the Non-Profit Institutions Act, 15 U.S.C. § 13c, to sales of pharmaceuticals by non-profit hospitals to related non-profit long-term care facilities ( )
- Presentation Health System ( )
- American Society of Internal Medicine ( )
- Advisory opinion concerning the legality of the American Society of Internal Medicine's proposal to develop and disseminate relative value guides ( )
- Order to File Special Report Regarding Physician Group and Healthcare Facility Mergers ( )
- Order to File Special Report to Collect Information Regarding Certificates of Public Advantage (COPA) ( )
- Prices for Medical Services Vary Within Hospitals, But Vary More Across Them ( )
- Simulating Hospital Merger Simulations ( )
- The effects of physician and hospital integration on Medicare beneficiaries’ health outcomes ( )
- Why is Distance Important for Hospital Choice? Separating Home Bias from Transport Costs ( )
- Price Effects of a Merger: Evidence from a Physicians’ Market ( )
- Federal Trade Commission Staff Report on the Homeopathic Medicine & Advertising Workshop ( )
- Direct-to-Consumer Advertising and Online Search ( )
- Competition in the Pet Medications Industry: Prescription Portability and Distribution Practices ( )
- Agreements Filled With the Federal Trade Commission Under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003: Overview of Agreements Filed In Fiscal Year 2013: A Report By the Bureau of Competition ( )
- Banning Foreign Pharmacies from Sponsored Search: The Online Consumer Response ( )
- Self-Regulation in the Alcohol Industry: Report of the Federal Trade Commission ( )
- Policy Perspectives: Competition and the Regulation of Advanced Practice Nurses ( )
- Economics at the FTC: Physician Acquisitions, Standard Essential Patents, and Accuracy of Credit Reporting ( )
- Agreements Filed With the Federal Trade Commission Under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003: Overview of Agreements Filed in Fiscal Year 2012: A Report by the Bureau of Competition ( )
- Agreements Filed With the Federal Trade Commission Under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003: Overview of Agreements Filed in Fiscal Year 2011: A Report by the Bureau of Competition ( )
- Agreements Filed With the Federal Trade Commission Under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003: Overview of Agreements Filed in Fiscal Year 2010: A Report by the Bureau of Competition ( )
- Agreements Filed With the Federal Trade Commission Under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003: Summary of Agreements Filed in Fiscal Year 2009: A Report by the Bureau of Competition ( )
- Agreements Filed With the Federal Trade Commission Under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003: Summary of Agreements Filed in Fiscal Year 2008: A Report by the Bureau of Competition ( )
- FTC Staff Submission to NYS Health Department Regarding the COPA Application of SUNY Upstate Medical University and Crouse Health System ( )
- FTC Staff Comment to Department of Veterans Affairs Concerning Authority of VA Professionals to Practice Healthcare ( )
- FTC Staff Comment to Texas Health and Human Services Commission Regarding Certificate of Public Advantage Applications ( )
- FTC Staff Comment to Attorney General of Texas Concerning Certified Registered Nurse Anesthetists (CRNA) Regulations ( )
- FTC Staff Letter to the Centers for Medicare and Medicaid Services Regarding the Interim Final Rule with Policy and Regulatory Revisions in Response to the COVID-19 Public Health Emergency ( )
- FTC Staff Letter to Department of Health and Human Services Concerning the 21st Century Cures Act: Interoperability, Information Blocking and the ONC Health IT Certification Program Rule ( )
- FTC Staff Comment to the Ohio House of Representatives Concerning Ohio House Bill 177 ( )
- FTC Staff Comment to the Kansas House of Representatives Concerning Kansas House Bill 2412 ( )
- FTC Staff Comment to the North Carolina State Board of Dental Examiners Regarding Proposed Rule Changes to 21 N.C. Admin. Code 16W ( )
- Comment of the Staff of the Federal Trade Commission to Massachusetts Rep. Paul J. Donato regarding HB1869 and SB1329 ( )
- FTC Staff Comment Before the Department of Health and Human Services Regarding the 21st Century Cures Act: Interoperability, Information Blocking, and the ONC Health IT Certification Program ( )
- FTC Staff Comment to the FDA Department of Health and Human Services on Its Updated Guidance for Industry on the “Nonproprietary Naming of Biological Products” ( )
- Statement of the Federal Trade Commission to the Alaska Senate Committee on Health & Social Services on Certificate of Need Laws and SB 1 ( )
- Federal Trade Commission Comment On the Food and Drug Administration’s Revised Draft Guidance For Industry, Entitled “Citizen Petitions and Petitions For Stay of Action Subject To Section 505(q) of the Federal Food, Drug, and Cosmetic Act.” ( )
- FTC Staff Comment on New York's proposal to allow licensure by endorsement of Canadian dental licenses ( )
- FTC Staff Comment to Washington State Rep. Paul Graves, regarding S.S.B. 5411/H.B. 1473 ( )
- Federal Trade Commission Staff Comment Before the Pennsylvania State House of Representatives Regarding the Likely Competitive Impact of House Bill 100 On Advanced Practice Registered Nurse-Certified Nurse Practitioners ( )
- FTC Staff Comment Before the Georgia Department of Community Health Regarding the Certificate of Need Application Filed by Lee County Medical Center ( )
- FTC Staff Comment To the Ohio State Senate Regarding the Competitive Effects of SB 330 In Increasing Access To Quality Dental Care, Including Its Provisions For Licensing Dental Therapists ( )
- FTC Staff Comment To the Delaware Board of Speech/Language Pathologists, Audiologists and Hearing Aid Dispensers Regarding Its Proposed Revisions To Its Telecommunication and Telehealth Regulations ( )
- Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC ( )
- SmileDirectClub, LLC v. Battle, et al. ( )
- D. Blaine Leeds and SmileDirectClub, LLC v. Jackson, et al. ( )
- Takeda Pharmaceutical Company Limited, et al. v. Zydus Pharmaceuticals (USA) Inc., et al. ( )
- Amphastar Pharmaceuticals, Inc., et al. v. Momenta Pharmaceuticals, Inc., et al. ( )
- Mylan Pharmaceuticals Inc. v. Warner Chilcott PLC ( )
- Teladoc, Incorporated, et al. v. Texas Medical Board et al. ( )
- In re Wellbutrin Antitrust Litigation ( )
- Mylan Pharmaceuticals, Inc. v. Warner Chilcott plc, et al. ( )
- Wellbutrin XL Antitrust Litigation, In re ( )
- In re K-Dur Antitrust Litigation ( )
- Arkansas Carpenters Health and Welfare Fund, et. al v. Bayer AG, et. al (In re Ciprofloxacin Hydrochloride Antitrust Litigation) ( )
- In re Ciprofloxacin Hydrochloride Antitrust Litigation ( )
- In re DDAVP Direct Purchaser Antitrust Litigation ( )
- In re Tamoxifen Citrate Antitrust Litigation ( )
- Teva Pharmaceuticals USA, Inc. v. Pfizer, Inc. ( )
- Andrx Pharmaceuticals, Inc. v. Kroger Co ( )
- Jackson, Tennessee Hospital Co. v. West Tennessee Healthcare, Inc ( )
- Teva Pharmaceuticals USA, Inc. v. Pfizer, Inc. ( )
- SmithKline Beecham Corp. v. Apotex Corp. ( )
- Stopping COVID-19 Fraud and Price Gouging ( )
- Prepared Statement of the Federal Trade Commission: Curbing COVID Cons: Warning Consumers about Pandemic Frauds, Scams, and Swindles ( )
- Prepared Statement of the Federal Trade Commission On “Oversight of the Enforcement of the Antitrust Laws” ( )
- Prepared Statement of the Federal Trade Commission On "Oversight of the Enforcement of the Antitrust Laws" ( )
- Prepared Statement of the Federal Trade Commission On Pay-For-Delay Deals: Limiting Competition and Costing Consumers ( )
- Prepared Statement of the Federal Trade Commission, "Oversight of the Enforcement of the Antitrust Laws" ( )
- Prepared Statement of the Federal Trade Commission on Antitrust Enforcement in the Health Care Industry ( )
- Prepared Statement of the Federal Trade Commission: Oversight of the Federal Trade Commission Bureau of Competition and the Department of Justice Antitrust Division ( )
- Prepared Statement of the Federal Trade Commission Concerning "The Community Pharmacy Fairness Act of 2007" ( )
- Prepared Statement of the Federal Trade Commission On Protecting Consumer Access To Generic Drugs: The Benefits Of A Leglislative Solution To Anticompetitive Patent Settlements In The Pharmaceutical Industry ( )
- Prepared Statement of the Federal Trade Commission On Internet, and Intellectual Property ( )
- Prepared Statement of the Federal Trade Commission On Health Care Competition ( )
- Prepared Statement of the Federal Trade Commission On Health Care Competition ( )
- Prepared Statement of the Federal Trade Commission On Generic Drug Entry ( )
- Prepared Statement of the Federal Trade Commission On Subcommittee on Federal Financial Management, Government Information, and International Security of the Committee on Homeland Security and Governmental Affairs, United States Senate ( )
- Prepared Statement of the Federal Trade Commission On Contact Lens Legislation ( )
- Prepared Statement of the Federal Trade Commission On Greater Access to Affordable Pharmaceuticals Act ( )
- Prepared Statement of the Federal Trade Commission On Competition In the Pharmaceutical Industry ( )
- Prepared Statement of the Federal Trade Commission On Competition in the U.S. Pharmaceutical Industry ( )
- Prepared Statement of the Federal Trade Commission On Pharmaceutical Industry ( )
